cells both directly through paracrine and autocrine effects and indirectly by promoting the survival of a pool of functionally incompetent T cells in the leukemic microenvironment. The differential effect on T-cell activation/proliferation and apoptosis strongly suggests that TSN contains multiple factors, which target these processes individually. Our results highlight the complexity of immune dysfunction within the leukemic microenvironment. Characterization of these findings will be important for understanding the mechanisms of disease progression and in the design of immunologically based strategies. Bortezomib inhibits the activation of nuclear factor Kappa B (NFkB), induces apoptosis of cancer cells, and presents a marked antitumoral activity in multiple myeloma.
Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect TO THE EDITOR High-dose therapy and autologous stem cell transplantation is still considered as the standard therapy for the treatment of highrisk multiple myeloma. However, immunotherapy through graftvs-myeloma effect can be observed after reduced intensity allogeneic stem cell transplantation. 1 Recently, new drugs such as antiangiogenic thalidomide and more recently proteasome inhibitor bortezomib 2 have opened new directions for the treatment of multiple myeloma.
Bortezomib inhibits the activation of nuclear factor Kappa B (NFkB), induces apoptosis of cancer cells, and presents a marked antitumoral activity in multiple myeloma. 3 A phase II study of bortezomib in relapsed refractory multiple myeloma showed a response rate of 35%. 4 Studies are ongoing to evaluate bortezomib in association to chemotherapy and as primary treatment for newly diagnosed multiple myeloma.
Despite the antitumor activity of bortezomib in multiple myeloma, its efficiency in plasmocytomas has not been reported yet. We report here on a patient with refractory multiple plasmocytomas who relapsed after reduced intensity allogeneic stem cell transplantation and multiple donor lymphocyte infusions. This patient showed a rapid complete remission after bortezomib administration.
A 58-year-old man who diagnosed with a stage IIIA Ig Gamma Kappa multiple myeloma according to Salmon and Durie classification with a cervical plasmocytoma. At diagnosis, a paraprotein was found at 35 g/l; the b 2 microglobulin and calcemia were both within normal values ; there was no bone lesion on standard X-ray and CT scan, the renal function was normal with no detectable Bence-Jones proteinuria. Cytogenetics were normal with no abnormality of chromosome 13. The first-line therapy consisted of five VAD chemotherapy regimens (vincristine, doxorubicin, dexamethasone) associated with fractionned local irradiation of the cervical plasmocytoma (30 Grays total dose). The paraprotein decreased from 35 g/l to undetectable levels by immunofluorescence; the size of the plasmocytoma remained stable as attested by CT scan. The patient received high-dose melphalan (200 mg/m 2 ) with autologous peripheral blood stem cell rescue. A first complete remission was achieved with undetectable plasmocytoma on CT scan (Table 1) .
After 8 months , the patient relapsed with bone pain, multiple osteolytic lesions on standard X-rays, hypercalcemia, and an increased level of the paraprotein (51 g/l). Four additionnal VAD regimens were given and a second intensification with high-dose melphalan (140 mg/m 2 ) and autologous peripheral blood stem cell rescue. Then a related HLA-identical nonmyelo-ablative peripheral blood stem cell transplant was carried out in an effort to control the disease through graft-vs-tumor effect. The reduced intensity conditioning regimen consisted of fludarabin 30 mg/m 2 for 4 days and i.v. busulfan 0.8 mg/kg twice a day for 2 days. A combination of cyclosporin A and a short course of i.v. methotrexate was used for graft-versus-host disease (GVHD) prophylaxis. PCR analysis for chimerism revealed 100% donor cells on bone marrow mononuclear cells, the CD3 þ fraction and the CD3À fraction. The patient did not develop acute GVHD and entered a second complete remission with undetectable paraprotein in the serum and no measurable plasmocytoma on CT scan.
Aftre 10 months , while host cells were still undetectable on total peripheral blood, CD3 þ and CD3À subpopulations by quantitative real-time PCR 5 (sensitivity 10
À4
), a second relapse occurred with multiple plasmocytomas and an increased paraprotein level at 27 g/l. Despite two DCEP chemotherapy regimens (dexamethasone, cyclophosphamide, etoposide, and prednisone) associated to local irradiation and five consecutive donor lymphocyte infusions, the patient showed tumor progression. Thalidomide and additional VAD regimen were attempted without response.
Introduction of the proteasome inhibitor bortezomib was decided as salvage therapy after an informed consent was obtained from the patient, according to the French regulation at that time. The serum level of the paraprotein was 21 g/l and was associated to several plasmocytomas at the following localizations on CT scan: one thoracic paravertebral (size: 21 Â 7 mm), one latero-pericardic (size: 35 Â 45 mm), two retroperitoneal (sizes 57 Â 54 and 35 Â 26 mm), and one periduodenal (size 46 Â 59 mm) (Figure 1 ). Bortezomib was given intravenously at a dose of 1.3 mg/m 2 on days 1, 4, 8, and 11 of a 21-day cycle. After two cycles, the plasmocytomas became undetectable by CT scan (Figure 2 ) and concomitantly, the paraprotein dropped from 21 to 3.9 g/l. The patient received two additionnal cycles. Grade 1 side effects related to bortezomib infusion consisted of peripheral neuropathy and postural hypotension. Consequently, further doses were reduced to 1.0 mg/m 2 for two additional cycles and to 0.7 mg/m 2 for the two next cycles. After 6 months of treatment with bortezomib the patient is still clinically improved and the neuropathy has improved. No bacterial, viral, or fungal infections have occured. A third complete remission has been achieved, attested by the absence of serum paraprotein and no detectable plasmocytoma. The chimerism has remained stable with 100% donor cells in peripheral blood.
This case report is illustrative of an unexpected and indeed high efficacy of bortezomib in an end-stage patient with MM in full-blown relapse with multiple progressing plasmocytomas. The patient had previously received four lines of treatment including conventional chemotherapy with VAD and DCEP, two courses of high-dose melphalan with autologous stem cell transplantation, a reduced intensity allogeneic stem cell transplantation with donor lymphocyte infusions, and thalidomide. Despite the persistence of a full donor cell chimerism after the allogeneic transplant and later after donor lymphocyte infusions, there was no GVHD in our patient and likewise no graft-vs-myeloma effect and no control of myeloma recurrence. 6 The admininistration of bortezomib after allogeneic stem cell transplantation in our patient resulted in the disappearance of the plasmocytomas. The high antitumor effect observed may be not only secondary to the direct action of bortezomib on tumor cells, but also may result from an enhancement of graft-vs-tumor effect (GVT). In fact, the proteasome inhibitor bortezomib has been shown to sensitize tumor cells to T-cell-mediated killing while inhibiting acute GVHD in a mouse model. 7 We hypothesize, to Correspondence explain the response, that a GVT effect was initiated in this patient who had received previously an allogeneic stem cell transplantation and donor lymphocyte infusions, on top of the targeted action of the drug itself on tumor cells.
Bortezomib appears to be an important new drugs in multiple myeloma, and according to our observation, may have a specific effect in two particular situations, that is, on plasmocytomas and postallogeneic stem cell transplantation. As previously shown, when patients have responded to bortezomib, they can experience an improvement of life expectancy without suffering from severe adverse effects. 2 Bortezomib is now tested in clinical trials as first-line therapy in association with thalidomide and dexamethasone (Alexanian et al. Blood 2004; 104: 64a; abstract).
We suggest bortezomib to be considered in patients with plasmocytomas and to rescue or prevent relapse after allogeneic stem cell transplantation. Based on experimental data, Zuna et al 1 offer a novel explanation of 'late' relapse in childhood ALL and argue persuasively that this explains the striking responsiveness of such off treatment relapses to retreatment. Their explanation of such relapses may also throw light on the requirement for maintenance (continuation) therapy in childhood ALL -a need which is empirically established but which lacks a theoretical basis. Pui for example states, 'For reasons that are poorly understood, children with ALL (except those with mature B-cell leukemia) require long-term continuation treatment. 2 ' It is striking in this context that prolonged maintenance therapy appears to be required only for 'classic' pre-B childhood ALL, not for mature B-or T-cell ALL -this is precisely the subtype for which Greaves has developed an elegant and widely accepted model of pathogenesis. 3 The essence of the Greaves' hypothesis is that childhood leukemia of this subtype is the consequence of a pre-or perinatal event creating a preleukemic clone; he further proposes that emergence of a leukemia clone is a consequence of an aberrant immune response and that this is most likely to occur when there is a delay in the normal pattern of exposure of an infant's immune system to infection. It is clear that childhood leukemia is not merely a consequence of relative immune deficiency since children do not develop the types of cancer commonly seen in immunosuppressed adults, and adults, in turn, do not develop typical childhood leukemia when immunosuppressed. McNally and Eden 4 have published a review of the evidence relating to an infectious etiology of childhood leukemia.
Zuna et al propose that 'late' relapses represent a new secondevent, triggering a new leukemic subclone from a persistent preleukemic population present at conclusion of remission induction and consolidation (intensification). This is highly plausible given that, at the time a child enters maintenance therapy, their immune system is likely to have been largely or even completely ablated by therapy already received. As a consequence, the immune system must be re-established in a process similar to that which normally occurs within the first year of postnatal life. The Greaves' hypothesis would predict that there would be a period during which the child may experience an aberrant immune response on exposure to a common infection(s), leading to emergence of a 'new' leukemic population. The different duration of maintenance therapy required (2 years for girls and 3 years for boys) may reflect the time taken to re-establish appropriate immune responses to common infections thus eliminating the risk of an aberrant immune response. If this model is correct, the role of maintenance therapy may be to eradicate incipient 'new' leukemias before they attain clinical significance. The efficacy of low-dose therapy in this setting would then be explained as preventing expansion of an initially very small tumor cell population, rather than achieving eradication of a large established malignant population. As stated, this is consistent with the specificity of maintenance therapy to classic pre-B childhood ALL.
